Pharmacometrics in bacterial infections

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 14, Issue , 2014, Pages 229-258

  Sy, Sherwin K B ^b   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE AMPC; CEFTAZIDIME; LEVOFLOXACIN; QUINOLONE DERIVATIVE; RNA 16S; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL LOAD; COMPARTMENT MODEL; CYSTIC FIBROSIS; DRUG RECEPTOR BINDING; EC50; HOST RESISTANCE; HUMAN; KLEBSIELLA PNEUMONIAE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; PHARMACOMETRICS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCAL PNEUMONIA;

EID: 85065457794     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1304-6_8     Document Type: Article

References (103)

1. Aires JR, Kohler T, Nikaido H, Plesiat P (1999) Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 43:2624–2628
2. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics–pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86
3. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E (2009) Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 63:38–42
4. Bakker EP (1992) Aminoglycoside and aminocyclitol antibiotics: hygromycin B is an atypical bactericidal compound that exerts effects on cells of Escherichia coli characteristics for bacteriostatic aminocyclitols. J Gen Microbiol 138:563–569
5. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S (2004) Bacterial persistence as a phenotypic switch. Science 305:1622–1625
6. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149–158
7. Breen L, Aswani N (2012) Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 7:CD002767
8. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT (2009) Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:46–56
9. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D’hondt RE, Jusko WJ, Forrest A, Tsuji BT (2010) Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54:2051–2062
10. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10; quiz 11–12
11. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP (2012) Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:6137–6146
12. Dasgupta A (2007). Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 377:1–13
13. De Kraker ME, Davey PG, Grundmann H (2011) Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 8:e1001104
14. De Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR (2014) The pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV co-infected tuberculosis patients receiving antiretroviral therapy, managed on multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother (pii: AAC.03073-14; epub ahead of print)
15. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289–300
16. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13–22
17. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J (2004) elationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189:1590–1597
18. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A (2009) Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wildtype Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53:2266–2273
19. Drusano GL, Fregeau C, Liu W, Brown DL, Louie A (2010) Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 54:4368–4372
20. Drusano GL, Liu W, Kulawy R, Louie A (2011a) Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 55:5300–5305
21. Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A (2011b) Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia. Antimicrob Agents Chemother 55:2693–2695
22. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL (2010) Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54:1117–1124
23. Eagle H, Fleischman R, Musselman AD (1950a) Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med 9:280–299
24. Eagle H, Fleischman R, Musselman AD (1950b) The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum. J Bacteriol 59:625–643
25. Eagle H, Fleischman R, Levy M (1953a) “Continuous” vs. “discontinuous” therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med 248:481–488
26. Eagle H, Fleischman R, Levy M (1953b) On the duration of penicillin action in relation to its concentration in the serum. J Lab Clin Med 41:122–132
27. Fisher JF, Meroueh SO, Mobashery S (2005) Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev 105:395–424
28. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802–808
29. Garrett ER (1978) Kinetics of antimicrobial action. Scand J Infect Dis 14(Suppl):54–85
30. Garrett ER, Nolte H (1972) Kinetics and mechanisms of drug action on microorganisms. XIV. The action of fluorouracil, other uracils and derived nucleosides on the microbial kinetics of Escherichia coli. Chemotherapy 17:81–108
31. Garrett ER, Miller GH, Brown MR (1966) Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. J Pharm Sci 55:593–600
32. Gershenfeld NA (1999) The nature of mathematical modeling. Cambridge University Press, Cambridge.
33. Grasso S, Meinardi G, De Carneri I, Tamassia V (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13:570–576
34. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331–385
35. Hoepelman IM, Rozenberg-Arska M, Verhoef J (1988a) Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy 34(Suppl 1):21–29
36. Hoepelman IM, Rozenberg-Arska M, Verhoef J (1988b) Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet 1:1305–1309
37. Hoffman A, Stepensky D (1999) Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 16:571–639
38. Jorgensen JH, Ferraro MJ (2009) Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis 49:1749–1755
39. Juan C, Moya B, Perez JL, Oliver A (2006) Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother 50:1780–1787
40. Jumbe LNN, Drusano GL (2011) A model-based PK/PD antimicrobial chemotherapy drug development platform to simultaneously combat infectious diseases and drug resistance. In: Kimko HHC, Peck CC (eds) Clinical trial simulations. Springer, New York
41. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112:275–285
42. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL (2006) Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 50:310–317
43. Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892–895
44. Kahlmeter G, Brown DF, Goldstein FW, Macgowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A (2003) European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52:145–148
45. Kahlmeter G, Brown DF, Goldstein FW, Macgowan AP, Mouton JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O (2006) European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 12:501–503
46. Kullar R, Leonard SN, Davis SL, Delgado G JR, Pogue JM, Wahby KA, Falcione B, Rybak MJ (2011) Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 31:441–448
47. Langaee TY, Dargis M, Huletsky A (1998) An ampD gene in Pseudomonas aeruginosa encodes a negative regulator of AmpC beta-lactamase expression. Antimicrob Agents Chemother 42:3296–3300
48. Langaee TY, Gagnon L, Huletsky A (2000) Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob Agents Chemother 44:583–589
49. Li Y, Peris J, Zhong L, Derendorf H (2006) Microdialysis as a tool in local pharmacodynamics. AAPS J 8:E222–E235
50. Lo A, Beh J, De Leon H, Hallow MK, Ramakrishna R, Rodrigo M, Sarkar A, Sarangapani R, Georgieva A (2011) Using a systems biology approach to explore hypotheses underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies. In: Kimko HHC, Peck CC (eds) Clinical trial simulations. Springer, New York
51. Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL (2007) In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 51:3988–4000
52. Louie A, Liu W, Fikes S, Brown D, Drusano GL (2013) Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 57:2788–2792
53. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T (2000a) Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:2242–2246
54. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T (2000b) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3322–3327
55. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2007) Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51:1939–1945
56. Mielck JB, Garrett ER (1969) Kinetics and mechanisms of drug action on microorganisms. IX. Inhibitory action of lincomycin on Escherichia coli by microbial kinetics. Chemotherapy 14:337–355
57. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T (1999) Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:415–417
58. Mohamed AF, Nielsen EI, Cars O, Friberg LE (2012) Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 56:179–188
59. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004a) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942
60. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC JR (2004b) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700–1705
61. Mondorf AW, Bonsiepe C, Mondorf W (1989) Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide. Adv Exp Med Biol 252:307–312
62. Mouton JW, Vinks AA (2005) Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 44:201–210
63. Mouton JW, Vinks AA, Punt NC (1997) Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41:733–738
64. Mouton JW, Punt N, Vinks AA (2005) A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 27:762–772
65. Mouton JW, Punt N, Vinks AA (2007) Concentration–effect relationship of ceftazidime explains why the time above the MIC is 40 % for a static effect in vivo. Antimicrob Agents Chemother 51:3449–3451
66. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235–237
67. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, Macgowan A, Theuretzbacher U, Turnidge J (2011) Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updates 14:107–117
68. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, Macgowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G (2012) The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18:E37–E45
69. Mueller M, De La Pena A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48:369–377
70. Nielsen EI, Friberg LE (2013) Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053–1090
71. Nielsen EI, Viberg A, Lowdin E, Cars O, Karlsson MO, Sandstrom M (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51:128–136
72. Nielsen EI, Cars O, Friberg LE (2011) Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 55:4619–4630
73. Nolting A, Dalla Costa T, Rand KH, Derendorf H (1996) Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13:91–96
74. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2008) Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 52:204–210
75. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J 328:668
76. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D (1984) Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 26:870–875
77. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T (1996) Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21:713–724
78. Quale J, Bratu S, Gupta J, Landman D (2006) Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633–1641
79. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009a) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98
80. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009b) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325–327
81. Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4:519–527
82. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402
83. Sanfilippo A, Morvillo E (1968). An experimental model for the study of the antibacterial activity of the sulfonamides. Chemotherapy 13:54–60
84. Sanfilippo A, Schioppacassi G (1973) New approach to the evaluation of antibacterial activity of aminosidine. Chemotherapy 18:297–303
85. Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H (2008) PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 8:549–556
86. Schmidt S, Sabarinath SN, Barbour A, Abbanat D, Manitpisitkul P, Sha S, Derendorf H (2009) Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:5039–5045
87. Shakil S, Khan R, Zarrilli R, Khan AU (2008) Aminoglycosides versus bacteria—a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 15:5–14
88. Sideraki V, Huang W, Palzkill T, Gilbert HF (2001) A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation. Proc Natl Acad Sci U S A 98:283–288
89. Sobel ML, Mckay GA, Poole K (2003) Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 47:3202–3207
90. Spino M (1991). Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 9:169–210
91. Sy SK, Beaudoin ME, Schuck VJ, Derendorf H (2013) Modeling the potentiation of in vitro aztreonam activities by avibactam against four beta-lactam-resistant bacterial strains. Interscience Conference on Antimicrobial Agents and Chemotherapy, Poster A–1014
92. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL (2005) Bacterial-population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa. J Infect Dis 192:420–428
93. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL (2007a) The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51:744–747
94. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL (2007b) Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 195:1818–1827
95. Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M (2008) Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 52:3987–3993
96. Treyaprasert W, Schmidt S, Rand KH, Suvanakoot U, Derendorf H (2007) Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 29:263–270
97. Tsuji BT, Brown T, Parasrampuria R, Brazeau DA, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Hanna D, Bulitta JB (2012a) Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother 56:3712–3719
98. Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D (2012b) Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 67:2182–2190
99. Vinks AA, Van Rossem RN, Mathot RA, Heijerman HG, Mouton JW (2007). Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Antimicrob Agents Chemother 51:3049–3055
100. Walkty A, Decorby M, Lagace-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG (2011) In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 55:2992–2994
101. Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883–3886
102. Yano Y, Oguma T, Nagata H, Sasaki S (1998) Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87:1177–1183
103. Zhuang L, Sy SK, Xia H, Singh RP, Liu C, Derendorf H (2013) Characterization of the in vitro antimicrobial activity of vertilmicin alone and in combination with ceftazidime by using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Interscience Conference on Antimicrobial Agents and Chemotherapy, Poster A-017